Table 2 Chemo susceptibility of TUBO and TUBO-P2J cells
From: Intratumoral heterogeneity impacts the response to anti-neu antibody therapy
| Chemoreagent | IC50 | |
|---|---|---|
| TUBO | TUBO-P2J | |
| Carboplatin | 0.22 mg/ml | 4.97 mg/ml |
| Cisplatin | 4.2 ug/ml | 3.53 ug/ml |
| Cyclophosphamide | 0.15 mg/ml | 1.93 mg/ml |
| Daunorubicin | UD | 326 ng/ml |
| Doxoruibicin | 56.9 ng/ml | 306.6 ng/ml |
| Epirubicin | 2.87 ng/ml | 40.3 ng/ml |
| Etoposide | 84 ug/ml | 76.63 ug/ml |
| Gemcitabin | 0.55 ng/ml | 6.4 ng/ml |
| Idarubicin | UD | 0.98 ug/ml |
| Irinotecan | 1.7 mg/ml | 0.95 mg/ml |
| Oxaliplatin | 0.26 ug/ml | 34.55 ug/ml |
| Vinorelbine | 0.23 ug/ml | 6.8 ug/ml |
